AI Portfolio Summary
In 2025 Q4, Catalio Capital Management, LP maintained a portfolio of 52 distinct positions. The most significant new addition to the portfolio was GILEAD SCIENCES INC, which now represents 6.28% of the total fund value. Conversely, Catalio Capital Management, LP completely exited their position in ABBVIE INC.
Total Positions
52
Quarter
2025 Q4
Top Holding
GILD (6.3%)
Top 10 Concentration
51.2%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
1-25 of 52
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
GILD
GILEAD SCIENCES...
|
Healthcare | 6.28% | — |
#1
Prev: #—
|
8.0 | 289,312 | no change |
NEW
|
289,312 | $35,510,155 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BMY
BRISTOL-MYERS S...
|
Healthcare | 6.18% | — |
#2
Prev: #—
|
7.5 | 647,899 | no change |
NEW
|
647,899 | $34,947,672 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BSX
BOSTON SCIENTIF...
|
Healthcare | 6.07% | 4.75% |
#3
5
Prev: #8
|
5.9 | 97,456 | 37.1% |
P
S
|
360,428 | $34,366,810 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BBOT
BRIDGEBIO ONCOL...
|
Healthcare | 5.55% | — |
#4
Prev: #—
|
6.2 | 410,700 | no change |
NEW
|
410,700 | $31,414,443 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LLY
ELI LILLY & CO
|
Healthcare | 4.92% | 8.09% |
#5
4
Prev: #1
|
2.5 | -31,453 | -54.8% |
P
S
|
25,923 | $27,858,930 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DNTH
DIANTHUS THERAP...
|
Healthcare | 4.76% | 4.86% |
#6
1
Prev: #7
|
2.4 | -14,043 | -2.1% |
P
S
|
653,572 | $26,933,702 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ASND
ASCENDIS PHARMA...
|
Healthcare | 4.49% | 5.33% |
#7
2
Prev: #5
|
2.3 | -25,689 | -17.7% |
P
S
|
119,265 | $25,432,069 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SNDX
SYNDAX PHARMACE...
|
Healthcare | 4.44% | 4.59% |
#8
1
Prev: #9
|
1.8 | -417,910 | -25.9% |
P
S
|
1,196,807 | $25,144,915 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
JNJ
JOHNSON & JOHNS...
|
Healthcare | 4.42% | — |
#9
Prev: #—
|
5.3 | 120,840 | no change |
NEW
|
120,840 | $25,007,838 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
REGN
REGENERON PHARM...
|
Healthcare | 4.07% | 3.67% |
#10
2
Prev: #12
|
2.1 | -5,547 | -15.7% |
P
S
|
29,797 | $22,999,410 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GPCR
STRUCTURE THERA...
|
Healthcare | 3.11% | 3.37% |
#11
2
Prev: #13
|
1.2 | -398,909 | -61.2% |
P
S
|
252,901 | $17,589,265 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SLNO
SOLENO THERAPEU...
|
Healthcare | 2.95% | 5.23% |
#12
6
Prev: #6
|
1.7 | -57,905 | -13.8% |
P
S
|
360,340 | $16,683,742 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CYTK
CYTOKINETICS IN...
|
Healthcare | 2.90% | 4.59% |
#13
3
Prev: #10
|
1.2 | -193,200 | -42.8% |
P
S
|
258,381 | $16,417,529 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EW
EDWARDS LIFESCI...
|
Healthcare | 2.82% | — |
#14
Prev: #—
|
4.6 | 187,048 | no change |
NEW
|
187,048 | $15,945,842 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ISRG
INTUITIVE SURGI...
|
Healthcare | 2.72% | 5.90% |
#15
11
Prev: #4
|
1.1 | -44,134 | -61.9% |
P
S
|
27,209 | $15,410,089 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NTRA
NATERA INC
|
Healthcare | 2.52% | 4.42% |
#16
5
Prev: #11
|
1.0 | -86,096 | -58.0% |
P
S
|
62,273 | $14,266,122 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ADPT
ADAPTIVE BIOTEC...
|
Healthcare | 2.36% | 2.45% |
#17
3
Prev: #20
|
1.4 | -63,695 | -7.2% |
P
S
|
821,195 | $13,336,207 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ABVX
ABIVAX SA
|
Healthcare | 2.35% | 2.54% |
#18
2
Prev: #16
|
0.9 | -63,627 | -39.2% |
P
S
|
98,514 | $13,285,105 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SUPN
SUPERNUS PHARMA...
|
Healthcare | 2.26% | 2.54% |
#19
2
Prev: #17
|
1.4 | -29,625 | -10.3% |
P
S
|
257,465 | $12,796,011 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GUTS
FRACTYL HEALTH ...
|
Healthcare | 2.14% | 1.53% |
#20
4
Prev: #24
|
2.9 | 277,630 | 5.3% |
P
S
|
5,491,866 | $12,082,105 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MLYS
MINERALYS THERA...
|
Healthcare | 2.13% | — |
#21
Prev: #—
|
4.4 | 331,849 | no change |
NEW
|
331,849 | $12,042,800 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PHAT
PHATHOM PHARMAC...
|
Healthcare | 2.05% | 2.46% |
#22
3
Prev: #19
|
0.8 | -429,525 | -38.1% |
P
S
|
698,996 | $11,596,344 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ADMA
ADMA BIOLOGICS ...
|
Healthcare | 1.82% | 1.86% |
#23
1
Prev: #22
|
1.2 | -120,047 | -17.5% |
P
S
|
564,461 | $10,295,769 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ACLX
ARCELLX INC
|
Healthcare | 1.80% | — |
#24
Prev: #—
|
4.2 | 156,109 | no change |
NEW
|
156,109 | $10,178,307 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DYN
DYNE THERAPEUTI...
|
Healthcare | 1.80% | — |
#25
Prev: #—
|
4.2 | 519,715 | no change |
NEW
|
519,715 | $10,165,625 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ABBV
ABBVIE INC
|
Healthcare | 0.00% | 6.63% |
Sold All 😨
(Was: #2) |
0.0 | -154,834 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BBIO
BRIDGEBIO PHARM...
|
Healthcare | 0.00% | 5.98% |
Sold All 😨
(Was: #3) |
0.0 | -622,729 | -100.0% |
CLOSED
|
— | $— | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EXAS
EXACT SCIENCES ...
|
Healthcare | 0.00% | 2.52% |
Sold All 😨
(Was: #18) |
0.0 | -248,987 | -100.0% |
CLOSED
|
— | $— | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RNA
AVIDITY BIOSCIE...
|
Healthcare | 0.00% | 2.12% |
Sold All 😨
(Was: #21) |
0.0 | -263,256 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CDTX
CIDARA THERAPEU...
|
Healthcare | 0.00% | 0.94% |
Sold All 😨
(Was: #28) |
0.0 | -53,333 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KYTX
KYVERNA THERAPE...
|
Healthcare | 0.00% | 0.65% |
Sold All 😨
(Was: #29) |
0.0 | -586,909 | -100.0% |
CLOSED
|
— | $— | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MLTX
MOONLAKE IMMUNO...
|
Healthcare | 0.00% | 0.18% |
Sold All 😨
(Was: #35) |
0.0 | -133,131 | -100.0% |
CLOSED
|
— | $— | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-25 of 52 holdings